Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
J Dig Dis 2017; 18(11):607-617JD

Abstract

Pharmacotherapy for nonalcoholic fatty liver disease (NAFLD) has not yet been approved by the US Food and Drug Administration. Over the past decade, a large number of clinical studies have explored the safety and efficacy of different drugs in treating nonalcoholic steatohepatitis (NASH), including diet pills, antioxidants, insulin sensitizers, lipid-lowering agents, anti-inflammatory cytokines, cytoprotective agents and intestinal probiotics. Based on the evidence from randomized controlled trials a number of academic groups have developed guidelines for the diagnosis and management of NAFLD and NASH. In this article, we discussed the current situation of NASH pharmacotherapy.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Shanghai Institute of Digestive Disease, Shanghai, China.Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Shanghai Institute of Digestive Disease, Shanghai, China.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29106066

Citation

Tang, Jie Ting, and Yi Min Mao. "Pharmacotherapy of Nonalcoholic Steatohepatitis: Reflections On the Existing Evidence." Journal of Digestive Diseases, vol. 18, no. 11, 2017, pp. 607-617.
Tang JT, Mao YM. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. J Dig Dis. 2017;18(11):607-617.
Tang, J. T., & Mao, Y. M. (2017). Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. Journal of Digestive Diseases, 18(11), pp. 607-617. doi:10.1111/1751-2980.12557.
Tang JT, Mao YM. Pharmacotherapy of Nonalcoholic Steatohepatitis: Reflections On the Existing Evidence. J Dig Dis. 2017;18(11):607-617. PubMed PMID: 29106066.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. AU - Tang,Jie Ting, AU - Mao,Yi Min, PY - 2017/07/22/received PY - 2017/09/05/revised PY - 2017/10/29/accepted PY - 2017/11/7/pubmed PY - 2018/8/8/medline PY - 2017/11/7/entrez KW - drug therapy KW - non-alcoholic fatty liver disease KW - nonalcoholic steatohepatitis KW - randomized controlled trial SP - 607 EP - 617 JF - Journal of digestive diseases JO - J Dig Dis VL - 18 IS - 11 N2 - Pharmacotherapy for nonalcoholic fatty liver disease (NAFLD) has not yet been approved by the US Food and Drug Administration. Over the past decade, a large number of clinical studies have explored the safety and efficacy of different drugs in treating nonalcoholic steatohepatitis (NASH), including diet pills, antioxidants, insulin sensitizers, lipid-lowering agents, anti-inflammatory cytokines, cytoprotective agents and intestinal probiotics. Based on the evidence from randomized controlled trials a number of academic groups have developed guidelines for the diagnosis and management of NAFLD and NASH. In this article, we discussed the current situation of NASH pharmacotherapy. SN - 1751-2980 UR - https://www.unboundmedicine.com/medline/citation/29106066/Pharmacotherapy_of_nonalcoholic_steatohepatitis:_Reflections_on_the_existing_evidence_ L2 - https://doi.org/10.1111/1751-2980.12557 DB - PRIME DP - Unbound Medicine ER -